Pancreatic Cancer: What About Screening and Detection?
Abstract
Pancreatic cancer is the fourth leading cause of cancer-related death in both sexes in the United States. In 2013, it is expected to account for 7% of all female cancer deaths and 6% of all male cancer deaths in the USA. Late presentation of the disease and poor prognosis even after complete operative resection, justify the necessity for early detection of pancreatic cancer as well as identifying high-risk individuals (screening). Herein, the authors summarize the data presented at the 2013 American Society of Clinical Oncology (ASCO) Annual Meeting regarding screening and early detection of pancreatic cancer (Abstracts #4045 and #4052).
Image: Salvation (Sotiria) mosaic. Antakya, Turkey.
Downloads
References
Tummala P, Junaidi O, Agarwal B. Imaging of pancreatic cancer: An overview. J Gastrointest Oncol.2011;2(3):168
Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63(1):11
Annaberdyev S. Pancreatic cancer. Online Preventative Medicine. 2008-2009. Case Western Reserve University
SEER Stat Fact Sheets: Pancreas (http://seer.cancer.gov/statfacts/html/pancreas.html)
Tersmette AC, Petersen GM, Offerhaus GJ, et al. Increased risk of incident pancreatic cancer among first-degree relatives of patients with familiar pancreatic cancer. Clin Cancer Res.2001;7(3):738
Lowenfels AB, Maisonneuve P, DiMagno EP, et al. Hereditary pancreatitis and the risk of pancreatic cancer. International Hereditary Pancreatitis Study Group. J Natl Cancer Inst.1997:89(6):442
Iqbal J, Ragone A, Lubinski J, et al. The incidence of pancreatic cancer in BRCA1 and BRCA2 mutation carriers. Br J Cancer.2012;107(12):2005
Giardiello FM, Brensinger JD, Tersmette AC, et al. Very high risk of cancer in familiar Peutz-Jeghers syndrome. Gastroenterology.2000;119(6):1447
Vasen HF, Gruis NA, Frants RR, et al. Risk of developing pancreatic cancer in families with familiar atypical multiple mole melanoma associated with a specific 19 deletion of p16 (p16-Leiden). Int J Cancer.2000;87(6):809
Kastrinos F, Mukherjee B, Tayob N, et al. Risk of pancreatic cancer in families with Lynch syndrome. JAMA.2009;302:1790
Wolpin BM, Chan AT, Hartge P, et al. ABO blood group and the risk of pancreatic cancer. J Natl Cancer Inst.2009;101(6):424
Howes N, Neoptolemos JP. Risk of pancreatic ductal adenocarcinoma in chronic pancreatitis. Gut.2002;51:765
Everhart J, Wright D. Diabetes mellitus as a risk factor for pancreatic cancer. A meta-analysis. JAMA.1995;273(20):1605
Wang F, Gupta S, Holly EA. Diabetes mellitus and pancreatic cancer in a population-based case-control study in the San Fransisco Bay Area, California. Cancer Epidemiol Biomarkers Prev.2006;15(8):1458
Silverman DT, Dunn JA, Hoover RN, et al. Cigarette smoking and pancreas cancer: a case-control study based on direct interviews. J Natl Cancer Inst.1994;86(20):1510
Boyle P, Maisonneuve P, Bueno de Mesquita B, et al. Cigarette smoking and pancreas cancer. A case-control study of the search programme of the IARC. IJC.1996;67(1):63
Bracci PM. Obesity and pancreatic cancer: overview of epidemiologic evidence and biologic mechanisms. Mol Carcinog.2012;51(1):53
Raderer M, Wrba F, Kornek J, et al. Association between Helicobacter pylori infection and pancreatic cancer. Oncology.1998;55(1):16
Misek DE, Patwa TH, Lubman DM, et al. Early detection and biomarkers in pancreatic cancer. J Natl Compr Canc Netw.2007;5(10):1034
Frebourg T, Bercoff E, Manchon N, et al. The evaluation of CA 19-9 antigen level in the early detection of pancreatic cancer: A prospective study of 866 patients. Cancer.1988;62(11):2287
Nam BH, Yu A, Woo S, et al. Development and validation of a predictive model to assess an individual’s risk of pancreatic cancer. J Clin Oncol.2013;31(suppl):abstract 4045
Schultz NA, Dehlendorff C, Jensen BV, et al. MicroRNA biomarkers in whole blood for detection of pancreatic cancer. J Clin Oncol.2013;31(suppl):abstract 4052
Wang W, Chen S, Brune KA, et al. PancPRO: risk assessment for individuals with a family history of pancreatic cancer. J Clin Oncol.2007;25:1417
Canto MI, Hruban RH, Fishman EK, et al. Frequent detection of pancreatic lesions in asymptomatic high-risk individuals. Gastroenterology.2012;142:796
Rulyak SJ, Brentnall TA. Inherited pancreatic cancer: surveillance and treatment strategies for affected families. Pancreatology.2001;1:477
Langer P, Kann PH, Fendrich V, et al. Five years of prospective screening of high-risk individuals from families with familiar pancreatic cancer. Gut.2009;58:1410
Canto MI, Harinck F, Hruban RH, et al. International Cancer of the Pancreas Screening (CAPS) Consortium summit on the management of patients with increased risk for familiar pancreatic cancer. Gut.2013;62(3):339
Wu E, Zhou S, Bhatt K, et al. CA 19-9 and pancreatic cancer. Clin Adv Hematol Oncol.2013;11(1):53
Locker GY, Hamilton S, Harris J, et al. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol.2006;24(33):5313
Bhat K, Wang F, Ma Q, et al. Advances in biomarker research for pancreatic cancer. Curr Pharm Des.2012;18(17):2439
Dutta SK, Girotra M, Singla M, et al. Serum HSP70: a novel biomarker for early detection of pancreatic cancer. Pancreas.2012;41(4):530
Li A, Yu J, Kim H, et al. MicroRNA array analysis finds elevated serum miR-1290 accurately distinguishes patients with low-stage pancreatic cancer from healthy and disease controls. Clin Cancer Res.2013 May 29 (Epub ahead of print)
Copyright (c) 2014 Froso Konstantinou, Kostas N Syrigos, Muhammad Wasif Saif
This work is licensed under a Creative Commons Attribution 4.0 International License.
As a member of Publisher International Linking Association, PILA, iMedPub Group’s JOP follows the Creative Commons Attribution License and Scholars Open Access publishing policies. Journal of the Pancreas is the Council Contributor Member of Council of Science Editors (CSE) and following the CSE slogan Education, Ethics, and Evidence for Editors.